CartaBio
Carta Bio is a pioneering company in the biotech sector that leverages scalable single-cell technology and AI to decode cellular intelligence, aiming to redefine drug discovery and develop next-generation immune-modulating therapeutics. Their innovative platform, known as the 'Carta Magna Of Cells', focuses on understanding cellular dysfunction through a cell-centric approach, which enhances target discovery and patient segmentation. With a strong team of experts from prestigious backgrounds, Carta Bio is positioned to make significant advancements in drug research and development, utilizing patented technologies to identify and modulate pathogenic cell states at an unprecedented scale.
CartaBio
Carta Bio is a pioneering company in the biotech sector that leverages scalable single-cell technology and AI to decode cellular intelligence, aiming to redefine drug discovery and develop next-generation immune-modulating therapeutics. Their innovative platform, known as the 'Carta Magna Of Cells', focuses on understanding cellular dysfunction through a cell-centric approach, which enhances target discovery and patient segmentation. With a strong team of experts from prestigious backgrounds, Carta Bio is positioned to make significant advancements in drug research and development, utilizing patented technologies to identify and modulate pathogenic cell states at an unprecedented scale.